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Abstract
Introduction: Rho GTPases are overexpressed and hyperactivated in human breast cancers. Deficiency of p190B
RhoGAP, a major inhibitor of the Rho GTPases, inhibits mouse mammary tumor virus long terminal repeat (MMTV)-
Neu/ErbB2 mammary tumor formation and progression in part through effects within the stromal environment,
suggesting that p190B function is pro-tumorigenic. To further investigate the potential pro-tumorigenic actions of
p190B, we examined the effects of exogenous p190B expression within the mammary epithelium on MMTV-Neu
tumor formation and progression.
Methods: Tetracycline (tet)-regulatable p190B transgenic mice were bred to MMTV-Neu mice, and the effects of
exogenous p190B expression on tumor latency, multiplicity, growth rates, angiogenesis, and metastasis were
examined. The effects of exogenous p190B expression on cell-matrix adhesion and invasion were tested using non-
transformed primary mammary epithelial cells (MECs). Rho GTPase activity, oxidative stress as an indicator of
reactive oxygen species (ROS) production, and downstream signaling pathways were analyzed.
Results: Altered p190B expression resulted in a two-fold increase in tumor multiplicity and a three-fold increase in
metastases compared to control mice indicating that exogenous p190B expression in the mammary epithelium
promotes MMTV-Neu mammary tumor formation and progression. Interestingly, non-transformed primary MECs
expressing exogenous p190B displayed increased adhesion to laminin and type IV collagen and formed invasive
structures in a three-dimensional culture assay. Ras related C3 botulinum toxin 1 (Rac1)-GTP levels were elevated in
p190B transgenic tumors whereas Ras homologous A (RhoA) and cell division cycle 42 (Cdc42)-GTP levels were not
significantly altered. Rac1 activity affects production of ROS, which regulate transformation, metastasis, and
oxidative stress. Protein carbonylation, which is indicative of oxidative stress, was elevated 1.75-fold in p190B
transgenic tumors as compared to control tumors suggesting that exogenous p190B expression may affect Rac1-
dependent ROS production.
Conclusions: These studies indicate that paradoxically, p190B RhoGAP, a major inhibitor of the Rho GTPases
in vitro, has pro-tumorigenic functions that enhance MMTV-Neu induced mammary tumor formation and
metastasis. Furthermore, exogenous p190B expression enhances cell adhesion and invasion, which may facilitate
metastasis. Rac1 activity and oxidative stress are elevated in tumors expressing exogenous p190B suggesting that
p190B may promote tumorigenesis through a Rac1/ROS dependent mechanism.
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Rho GTPases including RhoA, Rac1, and Cdc42 inte-
grate extracellular signals to affect a variety of cellular
processes such as proliferation, survival, and motility.
With their pleiotropic actions it is not surprising that
Rho GTPases have been implicated in nearly every stage
of breast tumor formation and progression [1]. Numer-
ous in vitro and relatively limited in vivo studies have
demonstrated that Rho GTPases affect transformation,
angiogenesis, invasion, and metastasis [2,3]. RhoA, Rac1,
Cdc42, and other family members are overexpressed
and hyperactivated in early and late stage human breast
tumors, and elevated RhoA and Rac1 expression corre-
lates with breast cancer progression [4,5]. Thus, Rho
GTPases are likely critical for human breast tumor for-
mation and metastatic progression (for review see [6]).
Rho GTPase activity is tightly regulated both spatially
and temporally in cells by positive regulators, guanine
nucleotide exchange factors (GEFs), and negative regula-
tors, GTPase activating proteins (GAPs) and guanine
nucleotide dissociation inhibitors (GDIs). Paradoxically,
some GDIs and GAPs, which are classically thought to
be negative regulators of the GTPases, have oncogenic
functions [7,8]. Furthermore, Rho GTPase activities vary
in different transformed cell lines, and it has been sug-
gested that the expression and activation profile of the
Rho GTPases may depend on the selective pressures
within a particular tumor [2]. Thus, how the complex
regulation of the Rho signaling network is altered during
the stochastic process of tumor formation and progres-
sion in vivo is not well understood. It is clear that there
is a need for in vivo studies investigating the role of this
multifaceted signaling network during mammary tumor-
igenesis, and this is what we aimed to do in our studies
investigating the effects of loss and gain of p190B func-
tion on MMTV-Neu mammary tumorigenesis.
P190B RhoGAP is a major regulator of Rho GTPases
[9]. In in vitro assays, p190B has GAP activity against
RhoA, Rac1, and Cdc42 [10]. P190B regulates Rac1
through direct interactions and RhoA indirectly [11].
P190B is also expressed in the developing embryonic
mammary anlagen and postnatal mammary gland [12].
Knockout of p190B perturbs embryonic mammary gland
development and prevents postnatal ductal morphogen-
esis indicating that p190B is essential for mammary
gland development [12,13]. We hypothesized that if
p190B is critical for mammary gland development it
might also play an important role during mammary
tumorigenesis.
To investigate the role of p190B in mammary tumori-
genesis we previously examined the effects of p190B
deficiency on MMTV-Neu induced tumor formation
and progression [8]. Loss of one allele of p190B delayed
tumor onset and reduced tumor penetrance. Further-
more, tumor angiogenesis was inhibited by p190B
heterozygosity. Reciprocal transplantation assays demon-
strated that p190B expression in the stroma and/or vas-
culature was likely critical for the angiogenic switch
needed to promote progression of preneoplastic lesions.
In addition to its effects on tumor formation, p190B
deficiency also inhibited lung metastasis when mice with
similar tumor burdens as wildtype mice were compared.
Thus, p190B plays an important role in the stromal
compartment during tumorigenesis and metastatic pro-
gression. However, because p190B was deficient in both
the stroma and epithelium it was difficult to assess
whether p190B expression in the epithelium was also
critical for tumor formation and progression. To address
this question we utilized tet-regulatable p190B trans-
genic mice in which p190B is inducibly expressed in the
mammary epithelium in response to doxycycline treat-
ment and activation of MMTV-driven reverse tetracy-
cline transactivator [14]. Here we show that p190B
expression in the mammary epithelium of MMTV-Neu
transgenic mice increases tumor multiplicity and metas-
tasis. Furthermore, non-transformed primary MECs iso-
lated from tet-regulatable p190B transgenic mice display
increased adhesion to basement membrane proteins and
give rise to invasive structures in a 3 D morphogenesis
assay. Thus, p190B regulates adhesion and invasion,
which may facilitate metastasis. P190B deficiency in
MMTV-Neu tumors decreased Rac1 activity. Conver-
sely, Rac1 activity levels were elevated in p190B trans-
genic tumors. Regulation of ROS-mediated signaling by
Rac1 has been implicated in oxidative stress, transforma-
tion, metastasis, and cell survival [15]. Intriguingly, pro-
tein carbonylation, an indicator of oxidative stress [16],
was elevated suggesting that ROS may be increased
downstream of Rac1 in tumors expressing exogenous
p190B. We propose that p190B may enhance transfor-
mation and metastasis through a Rac1/ROS dependent
mechanism. These results, together with our previous
studies [8], indicate that p190B may promote mammary
tumorigenesis in part by affecting Rac1-mediated
signaling.
Materials and methods
Mouse strains and tumor analysis
Tet-O-p190B-IRES-luciferase/MMTV-Neu bigenic mice
were bred to MMTV-rtTA/MMTV-Neu transgenic mice
to obtain trigenic Tet-O-p190B-IRES-luciferase/MMTV-
rtTA/MMTV-Neu (n = 27), and control Tet-O-p190B-
IRES-luciferase/MMTV-Neu (n = 19) and MMTV-rtTA/
MMTV-Neu (n = 28) bigenic mice. All mice were main-
tained on an FVB background. Genotypes were con-
firmed by PCR as previously described [8,14,17,18].
McHenry et al. Breast Cancer Research 2010, 12:R73
http://breast-cancer-research.com/content/12/5/R73
Page 2 of 16Beginning at 10 weeks of age, all mice were fed doxycy-
cline-containing chow (2g/kg ad libitum) for the duration
of the study. Mice were palpated weekly beginning at five
months of age and once tumors were detected, tumor
diameter was measured twice weekly with calipers. Mice
were euthanized when tumors reached 1 cm in diameter
or when tumor burden reached approximately 10% of
body weight in the case of multiple tumors. The Institu-
tional Animal Care and Use Committee of Baylor College
of Medicine approved animal protocols, and studies were
conducted in accordance with the provisions of the
Guide for the Care and Use of Laboratory Animals and
the Animal Welfare Act. Kaplan-Meier analysis was done
to determine tumor-free survival, and log-rank test analy-
sis was used to determine if differences between the three
groups were statistically significant. A Mann-Whitney
test was used to determine statistical significance of
tumor multiplicity results. An unpaired T-test was used
to evaluate the statistical significance of the tumor distri-
bution data. Error bars represent standard error of the
mean.
Tissue preparation and analysis
Mice were given an intraperitoneal injection of BrdU
(100 mg/kg) two hours prior to euthanization. Tumors
were dissected and divided into pieces that were either
fixed in 4% paraformaldehyde and paraffin embedded or
flash frozen. Lungs were also collected, fixed, and paraf-
fin embedded. Mammary gland pairs 2/3 and 4 were
dissected, fixed, and wholemount stained as previously
described [14]. Luciferase assays to detect transgene
expression in tumor lysates were done as previously
described [14]. Five μm serial sections of tumor and
lungs were cut for subsequent histological and immu-
nostaining analysis. Hematoxylin and eosin (H&E) stain-
ing was done using standard protocols. To quantify
metastasis, the number of metastatic lesions was
counted in H&E stained serial sections of the entire
lung from n =1 0m i c ep e rg e n o t y p e ,a n dA N O V Aw a s
used to evaluate statistical significance of these results.
Error bars represent standard error of the mean.
Rho GTPase activation assays
Activities of Rho family GTPases were measured using
luminescent (RhoA and Rac1) or colorimetric (Cdc42)
G-LISA assays (Cytoskeleton, Denver, CO, USA) accord-
ing to the manufacturer’s instructions. Frozen tumors
from p190B (n = 11) and rtTA/Neu mice (n =1 1 )w e r e
pulverized using a mortar and pestle and homogenized in
lysis buffer containing protease inhibitors (Cytoskeleton)
using a needle and syringe. The lysates were centrifuged
for two minutes/4°C/14,000 × g, and the clarified lysates
were aliquoted, snap frozen in liquid nitrogen, and stored
at -80°C. Protein concentration was determined using the
protein assay reagent provided. Immediately before the
assays, lysates were thawed and protein concentrations
were equalized to 2.0 mg/ml in lysis buffer. For the lumi-
nescent assays, SuperSignal West Dura chemiluminescent
substrate (Thermo Scientific, Rockford, IL, USA) was
substituted for the kit substrate, and a Kodak Gel Logic
1500 digital imaging system and Kodak 1 D software
(Carestream Health, New Haven, CT, USA) were used
to determine luminescent intensity. For the colorimetric
assay, a SpectraMax Plus 384 spectrophotometer and
SoftMax Pro software (Molecular Devices, Sunnyvale,
CA, USA) were used to determine absorbance. A Mann-
Whitney test was used to determine statistical signifi-
cance of the data. Error bars represent the standard error
of the mean.
Western blotting and luciferase assays
Protein lysates prepared for the G-LISA assays as
described above were utilized for Western blotting.
Sodium fluoride (20 mM) and sodium vanadate (1 mM)
phosphatase inhibitors were added to the samples and
equal amounts of protein from each of the 11 samples
were pooled prior to analysis. The pooled lysates were
electrophoresed on 6%, 8%, 12%, or 15% SDS-polyacryla-
mide gels, and transferred to PVDF membrane (Milli-
pore, Bedford, MA, USA). Membranes were blocked in
5% milk/TBS-Tween 20 followed by incubation with the
following antibodies and concentrations: p190B 1:250
(BD Bioscience, San Jose, CA, USA), ErbB2/Neu 1:1000
(Neomarkers, Fremont, CA, USA), ErbB3 1:1000
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
ERK-1/2 1:1000 (Cell Signaling, Danvers, MA, USA),
phospho-ERK-1/2 1:2000 (Cell Signaling), PAK-1/2/3
1:1000 (Cell Signaling), phospho-PAK1/2 1:1000 (Cell
Signaling), b-actin 1:2000 (Sigma, St. Louis, MO, USA),
MMP-3 1:200 (Santa Cruz), ROCK-II 1:200 (AnaSpec,
Fremont, CA, USA), pROCK/Thr396 1:200 (AnaSpec),
AKT 1:1000 (Cell Signaling), pAKT/Ser473 1:1000 (Cell
Signaling). Blots were incubated with Pierce West Dura
or West Femto Supersignal chemiluminescence reagent
(Thermo Scientific, Rockford, IL, USA), and imaged
using Kodak Gel Logic 1500 system. Densitometric
analysis of Western blots was done using the Kodak Gel
Logic system. Data were normalized to b-actin and
represent fold change compared to control samples.
RNA isolation and RT PCR
Frozen tumors were cooled with liquid nitrogen and
pulverized with a mortar and pestle. RNA was isolated
from the powder using Trizol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
recommendations. The RNA was treated with DNase I
and further purified using an RNeasy RNA purification
column (Qiagen, Valencia, CA, USA). One μg RNA was
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cDNA kit (Applied Biosystems, Carlsbad, CA, USA). As
a negative control, samples were prepared without
reverse transcriptase. GAPDH was amplified as an RT-
P C Rc o n t r o lg e n e .c D N Aw a sP C Ra m p l i f i e du s i n gt h e
same primers used for genotyping: 5’-CCT CAA AAA
GTC ATG GGG AAC GGA GC-3’ and 5’-CGC TGA
CAC GGT AGA GTC CTT CGG-3’. Reaction conditions
were: 94°C for 3 minutes, then 30 cycles of 94°C for
30 seconds, 60°C for 45 seconds, and 72°C for 45 sse-
conds, followed by 72°C for 5 minutes.
Oxidative stress assay
The OxyBlot assay (Millipore) was used according to the
manufacturer’s instructions. Equal amounts of protein
from 11 animals per genotype were electrophoresed on
a 4 to 15% gradient polyacrylamide SDS gel (Bio-Rad,
Hercules, CA, USA). West Dura chemiluminescence
reagent was used to develop the blot. Images were cap-
tured and data were quantified using the Kodak Gel
Logic system. Densitometry values represent fold change
relative to the control, and samples were normalized to
b-actin.
Immunostaining and quantification of staining
Immunohistochemistry was done as previously
reported [14] using biotin-conjugated BrdU 1:10 (BD
Pharmingen, 550803, San Diego, CA, USA), cleaved
caspase-3 1:400 (Cell Signaling), and CD31 1:500
(Abcam, Cambridge, MA, USA) in M.O.M block (Vec-
tor Labs, Burlingame, CA, USA). F4/80 1:50 (Abcam)
immunofluorescent staining was done as previously
described [19]. Two independent observers blinded to
the experimental groups assessed vascular density by
counting the number of vessels, n = 13, rtTA/Neu and
n = 11, p190B, an average of eight 400× fields were
counted per tumor, and proliferation by counting the
number of BrdU positive cells in a minimum of five
400× fields from each tumor. F4/80 staining was quan-
tified by counting a minimum of three 400× fields
from each tumor. Cleaved caspase-3 staining was
quantified by counting five 400× fields per tumor
representing approximately 10,000 cells, n =1 0t u m o r s
per genotype. Images were captured using a Zeiss
Axioimager epifluorescence microscope (Carl Zeiss,
Inc., Baden-Werttemburg, Oberkochen, Germany).
Isolation, culture, and immunostaining of primary MECs
MECs were isolated from mammary glands (MGs) of
paired 7 to 10 week-old MMTV-rtTA and tetO-p190B/
MMTV-rtTA mice. MGs were resected and placed in
ice-cold wash buffer (DMEM/F12 medium supplemen-
ted with 5% FBS, 50 μg/mL gentamicin, and 2.5 μg/mL
amphotericin B). MGs were minced and incubated in
digestion medium (DMEM/F12 medium supplemented
with 50 μg/mL gentamicin, 2.5 μg/mL amphotericin B,
2 mg/mL collagenase, and 100 U/mL hyaluronidase;
10 mL/g of tissue) shaking at 200 rpm at 37°C for one
hour. The digest was diluted with wash buffer and cen-
trifuged at 450 g/4°C/5 minutes. The fat and aqueous
layers were aspirated and discarded, and the cell pellet
was washed three times in ice-cold wash buffer, repeat-
ing the centrifugation conditions above. The cell pellet
was washed once in ice-cold PBS then incubated with
0.05% trypsin-EDTA shaking at 200 rpm at 37°C for
10 minutes. Following trypsin digest, ice-cold wash buf-
fer was added, and the cell suspension was filtered
through a 70 μm cell strainer. The strainer was rinsed
once with wash buffer to increase cell yield. The cells
were pelleted as before and resuspended in growth med-
ium (Clonetics MEGM complete medium, Lonza, Basel,
Switzerland) and seeded at a density of 2.5 × 10
6 cells
per well in a six-well plate pre-incubated with 1 mL/
well growth medium containing 2 mg/mL fetuin and
grown overnight. Non-adherent cells were removed by
two washes with PBS and discarded. Adherent cells
were detached with 0.05% trypsin-EDTA, diluted in
growth medium, pelleted, and resuspended in ice-cold
growth factor-reduced Matrigel (BD Biosciences,
San Jose, CA, USA) to a density of 7,500 cells per 40 μl
(per well of eight-well chamber slide). Matrigel contain-
ing MECs was pipetted onto chamber slides without
contacting walls, and the slides were incubated at 37°C
for 15 minutes. Growth medium containing 2% Matrigel
and 2 μg/mL doxycycline was added to the chamber
wells, and the cells were grown at 37°C/5% CO2/dark/
humidified for seven days. The medium was changed
every two to three days. For invasion assays, one hun-
dred structures were analyzed per experiment (n =4
experiments), t tests were used to compare means, and
error bars represent standard error of the mean. For the
inhibitor studies, ERK inhibitor (EMD Biosciences, San
Diego, CA, USA) was used at 20 μM and NSC23766
(Tocris Bioscience, Bristol, UK) was used at 25 μM.
Inhibitors were diluted in DMSO and added along with
doxycycline (2 μg/ml) when the cells were seeded.
Media was changed and inhibitors were added every
three days for one week. Cultures were fixed, stained
and analyzed as described below. One hundred struc-
tures were analyzed per experiment and the experiments
were repeated three times. T-tests were done to deter-
mine statistical significance of the data and error bars
represent standard error of the mean.
Immunofluorescence was performed according to
Debnath et al., using 2% paraformaldehyde as the fixative
[20]. The secondary blocking step was omitted. Primary
antibodies, atubulin 1:200 (Sigma Immunochemicals, St.
Louis, MO, USA), p190B 1:200 (BD Transduction Labs),
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Immunochemicals) were applied in primary blocking
solutions overnight at room temperature. Secondary anti-
bodies, goat anti-rabbit Alexafluor 488 and anti-mouse
Alexafluor 594, were used at 1:200. The slides were
mounted with Vectashield mounting medium containing
DAPI (Vector Laboratories, Servion, Switzerland), sealed
with nail polish, and stored at room temperature.
Adhesion assays
Primary MECs were isolated from p190B transgenic and
rtTA control mice that had been fed Dox chow (2 g/kg)
for three days to induce transgene expression and to
control for off-target effects of Dox, respectively. MECs
f r o mt h r e em a t u r ev i r g i nm i c ep e rg e n o t y p ew e r ei s o -
lated as described for invasion assays, except that the
washes following collagenase digestion were performed
at 600 × g/4°C/1 minute and repeated three to six times
to remove all erythrocytes. Isolated MECs were pooled
and plated on fetuin-coated plastic with growth medium
(DMEM/F12 supplemented with 5 μg/ml insulin, 1 μg/
mL hydrocortisone, 5 ng/mL epidermal growth factor
(EGF), 50 μg/ml gentamicin, 2.5 μg/mL amphotericin B,
and 5% FBS) and treated overnight with Dox (2 μg/ml)
to maintain transgene expression. Alternatively, cells
were frozen for later use in 90% FBS/10% DMSO and
seeded on fetuin-coated plastic upon thawing. Cells
were trypsinized, washed with serum-containing med-
ium to inactivate the trypsin, and transferred into 96-
well plates pre-coated with 15 μg/cm
2 of type I collagen,
type IV collagen, laminin, or fibronectin. After incuba-
tion at 37°C (two hours for collagen I, IV, and fibronec-
tin; three hours for laminin), non-adherent cells were
washed off with PBS. Remaining cells were incubated
with Cell Titer 96 Aqueous One Solution (Promega,
Madison, WI, USA) for one hour at 37°C, and absor-
bance at 490 nm was measured with a SpectraMax Plus
384 spectrophotometer and SoftMax Pro software
(Molecular Devices, Sunnyvale, CA, USA). Experiments
were performed in triplicate and repeated three times.
Means were compared using a t-test, and error bars
represent standard error of the mean.
Results
P190B transgene expression in the mammary epithelium
of MMTV-Neu mice increases tumor multiplicity
Previously we demonstrated that loss of one allele of
p190B markedly delayed MMTV-Neu tumor latency
and penetrance [8]. Because p190B was deficient in both
the epithelial and stromal compartments of the mam-
mary gland it was difficult to distinguish whether loss of
p190B in the epithelium impacted tumor initiation. To
determine the effects of epithelial expression of p190B
on mammary tumorigenesis we bred tetracycline-
regulatable p190B transgenic mice to MMTV-Neu mice.
Two different control groups, tet-O-p190B-IRES-lucifer-
ase/MMTV-Neu (n = 19) and MMTV-rtTA/MMTV-
Neu (n = 28) bigenic mice, were compared to exogenous
p190B expressing, tet-O-p190B-IRES-luciferase/MMTV-
rtTA/MMTV-Neu (n =27) trigenic female mice. For
simplicity we refer to the tet-O-p190B/MMTV-Neu
control group as tetO/Neu, the MMTV-rtTA/MMTV-
Neu control group as rtTA/Neu, and the p190B/
MMTV-rtTA/MMTV-Neu experimental group as
p190B.
We have previously shown that exogenous p190B
expression during virgin development delayed ductal
outgrowth, increased side branching, and resulted in dis-
organization of the ductal tree [14]. To ensure that
mammary gland developmental defects would not
impact tumor formation and progression, p190B trans-
gene expression was induced beginning at 10 weeks of
age. Mice were fed doxycycline (2 g/kg Dox containing
chow ad libitum for the duration of the study) to induce
transgene expression in the trigenic mice and to control
for any effects of doxycycline on mammary tumorigen-
esis and progression in the bigenic control groups.
Beginning at five months of age, mice were palpated
weekly to detect tumors, and the age of onset and loca-
tion of the tumor were recorded. In contrast to p190B
haploinsufficiency, which markedly delayed tumor onset,
p190B transgene expression did not affect tumor latency
(Figure 1a). The median time to tumor onset for each
group was approximately 280 days as determined by
Kaplan-Meier analysis. Although targeted expression of
p190B in the epithelium did not alter the timing of
tumor onset, it significantly increased tumor multiplicity
(Figure 1b). P190B transgenic mice developed an aver-
age of two tumors per mouse whereas single tumors
were detected in the majority of the control mice
(p190B vs. tetO/Neu, P = 0.004, p190B vs. rtTA/Neu,
P = 0.016). The distribution of tumors also differed sig-
nificantly between the control and p190B transgenic
mice. Compared to rtTA/Neu mice, p190B mice formed
more mammary tumors in the number 1 and 4 (44 +/-
10 vs. 14 +/- 7 percent of mice, P = 0.013) and 2/3
(93 +/- 5 vs. 61 +/- 9 percent of mice, P = 0.005) mam-
mary gland pairs (Figure 1c). Compared to tetO/Neu
mice, p190B mice formed more mammary tumors in
n u m b e r1( 4 4 + / - 1 0v s .1 1 + / - 7p e r c e n to fm i c e ,P =
0.013), and number 4 (44 +/- 10 vs. 16 +/- 9 percent of
mice, P = 0.042) mammary gland pairs. P190B and
tetO/Neu mice formed similar numbers of tumors in
the 2/3 (93 +/- 5 vs. 95 +/- 5 percent of mice, P > 0.05)
mammary gland pairs. Because tumor latency, multipli-
city, and distribution in the tetO/Neu mice were similar
to rtTA/Neu mice, we compared Dox-treated p190B
and rtTA/Neu mice for all subsequent analyses.
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increase tumor multiplicity by affecting expression of
the Neu transgene Western blotting was performed on
pooled lysates prepared from rtTA/Neu and p190B
tumors (n =11 tumors per genotype) (Figure 1d).
Because endogenous ErbB3 has been shown to be
important for MMTV-Neu induced tumorigenesis and
survival signaling through direct affects on AKT [21],
we also examined ErbB3 expression. Whereas ErbB2
expression levels were similar, we detected a slight
decrease in expression of full length ErbB3 and the
appearance of a smaller band suggesting that ErbB3
may be proteolytically cleaved in p190B tumors. To
verify transgene expression and to determine the
extent of exogenous p190B expression we performed
luciferase assays on tumor lysates from the p190B
transgenic mice and Western blotting to detect p190B
in the pooled tumor lysates. Luciferase was expressed
in 7/8 tumors from the p190B mice whereas, as
expected, none of 10 tumors from control mice
expressed luciferase (Figure 1e and data not shown).
We also performed RT-PCR on cDNA prepared from
rtTA/Neu and p190B tumors using primers that speci-
fically amplify the human p190B transgene, but not the
Figure 1 Exogenous expression of p190B increases tumor multiplicity. (a) Kaplan-Meier tumor-free survival curve of rtTA/Neu, tetO/Neu,
and p190B transgenic mice reveals that p190B does not affect MMTV-Neu tumor latency. The median time to tumor onset was approximately
275 days for each of the three groups. Log-rank test analysis showed no significant differences between the groups (P > 0.05). (b) P190B
transgenic mice developed an average of two tumors whereas control mice developed an average of one tumor per mouse indicating that
exogenous p190B expression increases tumor multiplicity. A Mann-Whitney test revealed statistically significant differences in tumor multiplicity
between the groups. (c) Tumor location by gland is graphed demonstrating statistically significant increased tumor formation in mammary
gland pairs 1, 4, and 2/3 in the p190B transgenic mice as compared to rtTA/Neu control mice (P < 0.05) and in mammary gland pairs one and
four compared to tetO/Neu control mice (P < 0.05). (d) Western blotting to detect expression of ErbB2/Neu, p190B, and ErbB3 in rtTA/Neu and
p190B transgenic tumors. Equal amounts of protein were pooled from 11 mice per genotype. Similar levels of ErbB2 and p190B were detected
in the two groups. Arrow indicates a lower molecular weight form of ErbB3 that was detected concomitant with a decrease in total protein in
p190B transgenic tumor lysates. b-actin is shown as a loading control. (e) Luciferase activity is graphed indicating that the tetO-p190B-IRES-
luciferase transgene is expressed in the majority of p190B tumors. Luciferase activity is never detected in control tumors. (f) RT-PCR on cDNA
prepared from exogenous p190B expressing and rtTA/Neu control tumors shows mRNA expression of the human p190B transgene in p190B
transgenic, but not rtTA/Neu control tumors. RT-PCR for GAPDH is shown as a positive control and samples prepared without RT were negative
(data not shown).
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4/5 p190B tumors expressed the human p190B trans-
gene mRNA, which was not detectable in any of the
rtTA/Neu control tumors (Figure 1f). Despite expres-
sion of luciferase and human p190B mRNA, which
indicated that the tetO-p190B-IRES-luciferase trans-
gene was active in the majority of tumors, overexpres-
sion of p190B was not detectable by Western analysis
(Figure 1d). This was not surprising as we were pre-
viously unable to detect overexpression of the p190B
transgene in the developing mammary glands of these
mice by Western blotting [14]. However, low levels of
p190B transgene expression in the developing mam-
mary gland rapidly and markedly altered terminal end
bud architecture and ductal morphogenesis [14]. In
addition, the majority, but not all of the tumors
expressed the p190B transgene, and thus, by pooling
tumor lysates from 11 mice we may have diminished
any small increases in p190B protein expression
detectable by Western blot. These results indicate that
p190B is not overexpressed at non-physiological levels
in this model and that even small or potentially transi-
ent increases in p190B expression in the mammary
epithelium affects MMTV-Neu induced mammary
tumorigenesis.
P190B and rtTA/Neu tumors have similar histologies,
proliferation, and apoptosis rates
Previously we demonstrated that p190B deficiency did
not impact the histology of the MMTV-Neu tumors
[8]. Similarly, exogenous expression of p190B did not
alter the histology of the tumors, which were classified
as poorly differentiated adenocarcinomas typical of
those found in MMTV-Neu transgenic mice [22]
(Figure 2a). Tumor growth rates were also not statisti-
cally different between theg r o u p sa sd e t e r m i n e db y
analysis of tumor volumes beginning from the time of
p a l p a t i o nu n t i lt h em i c ew e r ee u t h a n i z e d( F i g u r e2 b ) .
Analysis of BrdU incorporation, a marker of S phase,
indicated that proliferation rates were similar in p190B
transgenic and control tumors (4.1 +/- 0.13% vs. 4.9
+/- 0.49%, P > 0.05, n =6 tumors/group, a minimum of
5,000 cells/tumor were counted) (Figure 2a, c). To
evaluate whether p190B affects tumor cell survival we
quantified the number of cleaved caspase-3 (CC-3)
positive cells in tumor sections (five fields per tumor
representing approximately 10,000 cells were quanti-
fied, n =10 tumors per genotype). This analysis did not
reveal any differences in apoptosis rates in p190B
tumors compared to control tumors (1.14 +/- 0.32%
vs. 1.28 +/- 0.25%, P > 0.05) (Figure 2a, d). Thus, these
data indicate that exogenous p190B expression does
not alter differentiation, proliferation, or apoptosis in
MMTV-Neu tumors.
P190B transgene expression does not affect the
angiogenic switch
Haploinsufficiency for p190B blocked preneoplastic
progression by inhibiting angiogenesis [8]. To determine
whether exogenous p190B expression affected tumorigen-
esis by altering initiation and progression of preneoplastic
lesions we quantified the number of microscopic, non-
palpable lesions in whole-mounted mammary glands
from rtTA/Neu (n =17) and p190B (n =13) mice. Similar
numbers of preneoplastic lesions were detected in both
groups (1.2 +/- 0.27 vs. 1.5 +/- 0.24 preneoplastic lesions
per gland, P > 0.05) (Figure 3a, b). Furthermore, in con-
trast to p190B deficiency, which inhibited tumor angio-
genesis, exogenous p190B expression did not impact the
development of tumor vessels. Quantification of CD31
staining revealed that similar numbers of vessels were
present in tumors from control and p190B mice (21 +/-
1.9 vs. 26 +/- 2.4, P > 0.05) (Figure 3c). These results
suggest that exogenous p190B expression in the epithe-
lium does not promote tumor progression by impacting
angiogenesis.
Previously we showed that p190B transgene expression
in the developing mammary gland increased macro-
phage infiltration in association with aberrant terminal
end bud structures [14]. Macrophages have also been
shown to promote mammary tumor formation, invasion,
and metastasis [19,23]. To determine whether macro-
phage infiltration is altered by exogenous p190B expres-
sion, tumor sections were immunostained with the
macrophage marker F4/80 and the number of positive
cells were quantified in a minimum of three fields per
tumor (n =7 tumors per genotype). This analysis
demonstrated that there was no significant difference in
macrophage infiltration into the tumors (80 +/- 11 vs.
75 +/- 10, P > 0.05) (Figure 3d, e). Thus, macrophage
infiltration does not correlate with the increased tumori-
genesis detected in p190B transgenic mice. However,
these results do not rule out of the possibility of altered
activation of macrophages in the tumors expressing exo-
genous p190B.
P190B transgene expression increases cell adhesion,
invasion and lung metastasis
P190B deficiency inhibited primary tumor formation,
and metastasis was also significantly reduced when
p190B deficient mice were compared to wildtype mice
with similar tumor burdens [8]. To assess whether exo-
genous p190B expression affects metastasis the histo-
pathology and number of metastases were analyzed in
serial sections of lungs from tumor-bearing mice. Lung
metastases in both control and p190B mice resembled
undifferentiated adenocarcinomas, which are typical of
MMTV-Neu primary tumors (Figure 4a). Thus, p190B
transgene expression did not alter the histopathology of
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in the number of lung metastases was detected in p190B
transgenic mice (n =10, P = 0.024) as compared to
rtTA/Neu (n =10) and tetO/Neu mice (n =8) (Figure 4b
and data not shown). These data suggest that exogenous
p190B expression may promote metastatic progression.
To explore the mechanisms by which p190B may
enhance metastasis, we first tested whether exogenous
p190B expression affected cell adhesion to extracellular
matrix (ECM) proteins. Cellular adhesion to ECM plays
an important role in generating forces required during
migration and invasion [24]. For these experiments,
non-transformed primary MECs were isolated from
p190B/MMTV-rtTA mice and control MMTV-rtTA
mice lacking the Neu transgene that had been fed Dox
chow (2 g/kg) for three days to induce transgene expres-
sion. Once in culture, Dox (2 μg/ml) was added to both
cell types for the duration of the experiments. P190B
transgenic MECs were 1.5-fold (P = 0.012) and 4.5-fold
(P = 0.016) more adherent to the basement membrane
proteins type IV collagen and laminin, respectively, as
compared to MECs from control mice (Figure 4c). No
differences in adhesion to type I collagen or fibronectin
were detected.
To assess whether the increased adhesive capacity of
p190B transgenic MECs also affected cellular invasion,
we quantified the number of invasive structures that
formed when the primary MECs were grown in 3 D cul-
ture. This analysis demonstrated that exogenous expres-
sion of p190B in primary MECs promoted a two-fold
increase in invasion (P =0 . 0 3 5 ,n =400 structures per
genotype) (Figure 4d, e). Many of the invasive structures
displayed abnormal polarity and disrupted lumens, how-
ever, these phenotypes were not significantly different
Figure 2 P190B transgene expression does not affect tumor differentiation, proliferation, growth rates, or apoptosis. (a) H&E stained
tumor sections (400× magnification) demonstrate that p190B does not alter differentiation of MMTV-Neu tumors. Representative images of
immunostaining to detect BrdU incorporation and cleaved caspase 3 (200× magnification) in 5 μm tumor sections from rtTA/Neu and p190B
mice are shown. (b) Growth curves of p190B and rtTA/Neu control tumors are graphed. No statistical differences were detected in tumor growth
rates (t test, P > 0.05). Error bars represent the standard error of the mean. (c) Quantification of BrdU incorporation shows that exogenous p190B
expression does not affect tumor cell proliferation rates (t test, P > 0.05). (d) Cleaved caspase 3 (CC3) immunostaining is quantified and
demonstrates that p190B transgene expression does not affect tumor cell survival (t test, P > 0.05). Error bars represent the standard error of the
mean.
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cannot rule out the possibility that the increased tumor
multiplicity in p190B transgenic mice may have resulted
in more metastases, it appears likely that the enhanced
adhesive and invasive capacity of p190B transgenic
MECs facilitates metastasis of MMTV-Neu induced
mammary tumors.
We previously showed that altered p190B expression
affected signaling through Rac and ERK in the develop-
ing mammary gland and in MMTV-Neu tumors [8,14].
To determine whether the invasive phenotype is depen-
dent on signaling through Rac and/or ERK we treated
primary MECs from p190B transgenic and MMTV-rtTA
control mice in 3 D culture with Rac NSC23766 (25
μM) and ERK (20 μM) inhibitors and quantified effects
on lumen formation and invasion. As seen in Supple-
mental figure 1 in Additional file 1, neither inhibitor
alone blocked the effects of p190B trasgene expression
on invasion. In contrast, inhibition of Rac or ERK signif-
icantly increased invasion and disrupted lumen
formation and polarity in both control MMTV-rtTA
and p190B primary MECs indicating that both Rac and
ERK activities are important for normal morphogenesis
of primary MECs (Supplemental figure 1 in Additional
file 1). It is likely that multiple signaling pathways are
perturbed downstream of p190B, and the precise
mechanisms by which p190B affects invasion of primary
MECs remain to be elucidated.
Rac1 activity is elevated in tumors expressing exogenous
p190B
P190B has previously been shown to have GAP activity
against Rho, Rac, and Cdc42 [10]. More recently, p190B
was shown to directly interact with Rac1, but not RhoA
or Cdc42. However, RhoA activity was indirectly regu-
lated by p190B [11]. We previously demonstrated that
Rac1-GTP levels were reduced in p190B deficient
tumors [8]. To determine the effects of exogenous
p190B expression on Rho GTPase activities we per-
formed G-LISA assays on tumor lysates from rtTA/Neu
Figure 3 Exogenous p190B expression does not promote MMTV-Neu induced tumorigenesis by affecting the angiogenic switch.
(a) Whole-mount mammary glands from tumor-bearing mice were examined to detect hyperplastic lesions. Representative images are shown
with arrows indicating hyperplastic lesions. LN indicates lymph nodes. (b) The number of hyperplastic lesions were quantified in tumor-free
mammary glands pairs 2/3 and 4 from tumor-bearing mice (n =17 rtTA/Neu and n =13 p190B mice). No statistical differences were detected
(t test, P > 0.05). Error bars represent standard error of the mean. (c) Quantification of CD31 immunostaining in tumor sections from p190B
(n =11) and rtTA/Neu (n =13) mice demonstrates that p190B does not affect tumor angiogenesis. An average of eight 400× fields were counted
per tumor. No statistical differences were detected (t test, P > 0.05). Error bars indicate standard errors (d) F4/80 immunostaining to detect
macrophage infiltration in p190B and rtTA control tumors. F4/80 is shown in red and nuclei are blue. Representative 400× images are shown.
(e) Quantification of F4/80 immunostaining demonstrates that there is no difference in macrophage infiltration in p190B transgene expressing
tumors as compared to rtTA control tumors. Five 400× fields per tumor (n =7 per genotype) were quantified. No statistical differences were
detected (t test, P > 0.05). Error bars indicate the standard error of the mean.
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statistically significant increase in Rac1 activity levels in
p190B transgenic tumors (n =11, P = 0.014) as com-
pared to control tumors (n =11) (Figure 5a). No statisti-
cal differences were detected in the levels of RhoA or
Cdc42 activity. Elevated Rac1 activity promotes transfor-
mation and metastasis [25], and deficiency of the Rac-
GEF, Tiam1, inhibits MMTV-Neu tumor formation
[26]. Thus, p190B may facilitate tumor formation and
progression by enhancing Rac1 activity.
Rac1 regulates production of ROS, and ROS affect
tumorigenesis, metastasis, and cell survival [15,27,28].
Because it is not possible to directly measure ROS levels
in the tumors in situ, we assessed oxidative stress as an
indirect measure of altered ROS production. For this we
utilized the OxyBlot Western assay to assess protein
carbonylation in the pooled tumor lysates (n =11 per
genotype), which is indicative of oxidative stress [16]. As
seen in Figure 5b, protein carbonylation, was increased
1.75-fold in p190B transgenic tumors as compared to
Figure 4 P190B transgene enhances cell-ECM adhesion, invasion, and metastasis. (a) Exogenous p190B expression does not alter the
histopathology of MMTV-Neu lung metastases, which resemble undifferentiated adenocarcinomas that are typical of MMTV-Neu mice. (b)
Average number of metastases per mouse at tumor burden was determined by counting metastatic lesions in serial sections of the entire lung.
rtTA/Neu control mice had similar numbers of metastases as TetO/Neu mice (data not shown). ANOVA was used to determine statistical
significance between the groups. Error bars represent standard error of the mean. (c) P190B (black bars) and rtTA (gray bars) primary MECs were
analyzed for their ability to adhere to ECM proteins. An MTS assay was used as an indirect measurement of the number of adherent cells. Data
represent three independent experiments. A t test was used to determine statistical significance and error bars represent standard errors of the
mean. (d) Exogenous p190B expression promotes invasion as determined by confocal microscopic analysis of p190B and rtTA primary MECs
cultured in Matrigel for 12 days and immunostained to detect red = p190B, green =atubulin, blue = DNA. Arrows indicate invasive projections.
(e) The number of invasive structures was quantified (n =400 structures per genotype). A t test was used to determine statistical significance,
and error bars represent standard error of the mean.
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elevated downstream of Rac1 in the tumors expressing
exogenous p190B, although additional studies will be
required to prove this. Interestingly, expression of
MMP-3, which regulates ROS production through a
R a c 1 b - d e p e n d e n tm e c h a n i s m[ 1 5 ]a n di sa l s ou p r e g u -
lated by ROS [29], is elevated in p190B trasngenic
tumors (Figure 5c).
Next we examined the effects of p190B on down-
stream signaling within the tumors. For this, Western
blotting to detect phosphorylated and total levels of the
Rac1 effectors p21 activated kinase (PAK-1/2), the RhoA
effector Rho kinase (ROCK), and downstream signaling
molecules AKT and ERK was done on the pooled tumor
extracts from 11 mice per genotype. Paradoxically, PAK-
1/2, ROK, AKT, and ERK expression and/or activity
levels are diminished in p190B tumors as compared to
rtTA/Neu control tumors (Figure 5c). We have pre-
viously shown that sustained exogenous expression of
p190B in the developing mammary gland inhibits signal-
ing to these downstream effectors [14]. It is unclear why
these signaling molecules are not increased in the p190B
transgenic tumors to reflect the elevated Rac1 that was
detected in the tumors. Additional studies will be
required to dissect the molecular mechanisms underly-
ing the pro-tumorigenic effects of p190B.
Discussion
The Rho signaling network is perturbed during tumori-
genesis [1,30,31], and Rho GTPases are overexpressed
and hyperactivated in breast tumors [4,5,32]. In vitro
studies have shown that this signaling network has
pleiotropic functions and can regulate tumor cell prolif-
eration, survival, and migration [3]. Despite the wealth
of information available about how Rho GTPases affect
cellular processes and signaling in vitro, the cellular and
molecular mechanisms by which Rho GTPases affect the
stochastic process of tumor formation in the complex
in vivo environment are not well understood. We inves-
tigated this by examining the role of p190B RhoGAP, a
major inhibitor of Rho GTPases, during MMTV-Neu
induced mammary tumor formation and progression.
P190B is required for mammary gland development
[12-14], and we hypothesized that it would also be
Figure 5 Rac1 activity and oxidative stress are increased in p190B transgenic tumors. (a) G-LISA assays were used to quantify the levels of
active RhoA, Rac1, and Cdc42 in rtTA (n =11) and p190B (n =11) tumors. A Mann-Whitney rank sum test was used to compare the means, and
error bars represent standard error of the mean. Rac1 activity was elevated, however, RhoA and Cdc42 activities were not statistically significantly
different between the two groups. (b) An OxyBlot assay was performed to detect protein carbonylation as an indirect measure of ROS-mediated
oxidative stress. Western blot shows an increase in total carbonylated proteins after dinitrophenylhydrazine (DNP) derivitization in p190B
expressing tumor lysates compared to control lysates. Each lane represents equal amounts of protein pooled from 11 tumors per genotype. DNP
protein standards were included for size comparison. b-actin is shown as a loading control. Densitometry value represents the fold change in
carbonylated proteins in p190B tumors relative to control tumors. Control tumor values were set to 1 and samples were normalized to b-actin.
(c) Western blotting to detect expression of total and phosphorylated forms of downstream effectors of Rac1. b-actin is shown as a loading
control. Each lane represents equal amounts of pooled protein from 11 tumor lysates per genotype. Densitometry values represent the fold
change in protein expression in p190B transgenic tumors relative to control tumors. Control tumor values were set to 1 and samples were
normalized to b-actin.
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examined the effects of loss of p190B function on
MMTV-Neu tumorigenesis and showed that haploin-
sufficiency for p190B delayed tumor onset and
decreased tumor penetrance [8]. P190B was also defi-
cient in the stroma, and transplantation assays indi-
cated that its function in the stroma and/or
vasculature was important for the angiogenic switch
that is required to promote preneoplastic progression.
Although these studies suggested that p190B also
played an important role in the epithelium, it was diffi-
cult to assess this using the germline p190B knockout
mice. We, therefore, turned to tet-regulatable p190B
transgenic mice in which p190B is inducibly expressed
in the mammary epithelium in response to Dox
treatment.
Exogenous p190B expression enhanced MMTV-Neu
induced tumorigenesis as indicated by an increase in the
number of tumors that formed per mouse, which is con-
sistent with an increase in tumor formation in mam-
mary gland pairs one and four compared to control
mice. We did not detect a difference in the number of
preneoplastic lesions that formed in the p190B trans-
genic mice as compared to the control mice, nor did we
detect a statistically significant difference in tumor
angiogenesis. These data indicate that p190B expression
in the epithelium does not facilitate tumor formation by
affecting the angiogenic switch. Furthermore, these
results are consistent with our data demonstrating that
deficient expression of p190B in the stroma and/or vas-
culature affected progression of preneoplastic lesions in
MMTV-Neu mice [8].
Similar to the effects of p190B deficiency in MMTV-
Neu tumors [8], p190B transgene expression also had
no impact on tumor growth, proliferation rates, or
apoptosis as demonstrated by determination of tumor
volumes, and quantification of BrdU incorporation and
cleaved caspase-3 staining, respectively. Thus, p190B is
not likely promoting tumor formation by enhancing
proliferation or tumor cell survival.
In addition to promoting primary tumor formation,
exogenous p190B expression also increased metastasis.
Non-transformed p190B transgenic primary MECs
exhibited increased adhesion to basement membrane
proteins and formed invasive structures in a 3 D culture
morphogenesis assay. These experiments demonstrated
that even in the absence of an oncogenic stimulus,
p190B promotes cellular invasion. We propose that
these phenotypes contributed to the increase in metasta-
sis in the p190B transgenic MMTV-Neu mice. However,
we cannot rule out the possibility that the increase in
tumor burden due to the presence of multiple tumors in
the majority of p190B transgenic mice also impacted
metastasis.
We attempted to elucidate the molecular mechanisms
by which p190B facilitates invasion in primary non-
transformed MECs by testing whether inhibition of Rac
or ERK was sufficient to block the invasive phenotype
promoted by exogenous p190Be x p r e s s i o n .H o w e v e r ,
inhibition of either Rac or ERK throughout MEC mor-
phogenesis significantly perturbed polarity and lumen
formation and enhanced invasion regardless of p190B
expression. Dominant negative Rac1 expression has pre-
viously been shown to disrupt polarity and lumen for-
mation in primary MECs [33] so it was not surprising
that Rac inhibition promoted these phenotypes. P190B
transgene expression in the developing mammary gland
[14] and in MMTV-Neu tumors inhibited ERK activity,
a n di ti sp o s s i b l et h a ti n h i b ition of ERK activity contri-
butes to the invasive phenotype of p190B transgenic
mammary acini.
Initially we were surprised that ERK inhibition drama-
tically altered lumen formation and promoted invasion
in the majority of mammary acini in 3 D culture as sev-
eral studies have demonstrated that sustained or ele-
vated ERK activity promotes MEC transformation and
invasion [34-36]. In addition, elevated ERK activity has
been linked to poor prognosis in breast cancer [37].
Paradoxically, a number of other studies have demon-
strated that ERK signaling can have opposite phenotypic
effects in a cell type specific manner depending on the
level, duration, and cellular localization of the signal
[38]. Furthermore, elevated ERK activity has also been
linked to better prognosis in several studies of breast
cancer patients [39-41]. The seemingly paradoxical
impact of ERK activation on mammary transformation
and tumorigenesis may be dependent on the specific
genetic alterations within individual breast tumors or
cell lines, and the role of ERK activation should be con-
sidered within these specific contexts.
To further explore the molecular mechanisms under-
lying the pro-tumorigenic actions of p190B in MMTV-
Neu tumors, we examined the activity levels of RhoA,
Rac1, and Cdc42 in the tumors. We previously demon-
strated that loss of p190B function in MMTV-Neu
tumors leads to decreased Rac1 activity, and now con-
versely, we show that exogenous p190B expression
results in elevated Rac1 activation. Similar to the studies
in the p190B deficient mice, we did not detect statisti-
cally significant differences in RhoA or Cdc42 activities.
However, we cannot rule out the possibilities that activ-
ity of other GTPases may be altered or that RhoA and
Cdc42 are transiently regulated.
Rac1 has been implicated in transformation and
metastasis [25,42,43]. Deficiency of the Rac GEF Tiam1
in MMTV-Neu mice delayed tumor onset and decreased
metastasis suggesting that Rac1 activity plays a causal
role in MMTV-Neu induced tumor formation and
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us to hypothesize that Rac1 activity may be regulated by
p190B during MMTV-Neu mammary tumorigenesis and
that p190B may promote transformation and metastatic
progression via a Rac1 dependent mechanism. Addi-
tional studies will be required to demonstrate whether
p190B promotes tumorigenesis via a Rac-dependent
mechanism.
A major question raised by our studies is why loss and
gain of p190B function, which would be expected to
increase and decrease GTPase activity, respectively, has
the opposite effect on Rac1 activity? High GTPase activ-
ity and rapid turnover in the presence of elevated GAP
expression seem to be contradictory. Computational
modeling has suggested that although GAPs reduce
GTPase activity, the GTPase turnover rate increases
proportionally with increasing GAP concentration, and
ultimately, the balance between GAP and GEF concen-
trations is critical for high GTPase activity [44]. In addi-
tion, GTPase cycling rates in fast cycling mutants
increase the transforming capacity of the Rho GTPases
[45,46]. It is possible that through direct interactions,
p190B enhances the cycling rate of Rac1, thereby pro-
moting elevated Rac1 activity. P190B may also act as a
scaffold to bring together a large signaling complex at
the membrane, and thus, exogenous p190B expression
may increase Rac1 membrane localization and subse-
quent activity.
Another question raised by these studies is if Rac1
activity is elevated in p190B transgenic tumors, why is
signaling to the downstream effectors AKT and ERK
d i m i n i s h e d ?I ti si m p o r t a n tt on o t et h a tt h eW e s t e r n
analysis represents a fixed time point in late stage
tumors that may not be indicative of the early changes
in signaling that are responsible for tumor initiation and
progression. However, p190B transgene expression in
the developing mammary gland also inhibited signaling
to AKT and ERK suggesting that similar signaling path-
ways are altered downstream of exogenous p190B
expression during mammary gland development and
tumorigenesis [14]. In the p190B transgenic tumors the
expression levels of PAK and ROCK proteins were only
modestly decreased. Furthermore, phospho-ROCK was
elevated in p190B transgenic tumors suggesting that
despite effects on total protein levels, signaling through
ROCK may still be important for MMTV-Neu induced
tumorigenesis.
The Rho signaling network is highly complex, and it is
likely that multiple signaling pathways converge to mod-
ulate PAK, ROCK, AKT, and ERK. For example, ErbB2
and ErbB3 cooperate to promote MMTV-Neu induced
tumorigenesis, and activation of AKT and MAPK down-
stream of ErbB2/ErbB3 affects tumor cell proliferation
[21]. Interestingly, by Western analysis we detected a
slight decrease in expression of the full-length form of
ErbB3 concomitant with the appearance of a lower
molecular weight form suggesting that ErbB3 may be
proteolytically cleaved in the p190B transgenic tumors.
Consistent with this possibility we detected an increase
in MMP3 expression in the p190B transgenic tumors.
Furthermore, MMP-dependent cleavage of the related
ErbB4 produces a cytoplasmic fragment that regulates
tumor cell proliferation [47]. It is possible that decreased
expression of full length ErbB3 at the cell surface is
responsible for the diminished activation of the down-
stream effectors AKT and ERK in the tumors expressing
exogenous p190B. Future studies will be aimed at eluci-
dating how these complex signaling interactions regulate
MEC morphogenesis and invasion utilizing primary
MECs in the 3 D culture system.
To reconcile the apparent inconsistencies between the
pro-tumorigenic effects of exogenous p190B expression
and increased Rac1 activity with the diminished signal-
ing to the downstream effectors we considered the pos-
sibility that ROS were elevated downstream of p190B/
Rac1. ROS have been shown to act downstream of Rac1
to facilitate transformation and metastasis [15,28,48],
and in the presence of cellular stress, ROS promoted
oxidative stress, diminished ERK phosphorylation, and
cell death [49]. Because of the lack of an in situ assay to
detect ROS in the tumor tissue, we examined protein
carbonylation as an indicator of oxidative stress. Inter-
estingly, protein carbonylation is elevated suggesting
that oxidative stress may be increased in p190B trans-
genic tumors. Expression of matrix metalloproteases
(MMPs) is also regulated by ROS [29,50,51], and
MMP-3 was upregulated in the p190B transgenic
tumors as another potential indicator of an increase in
ROS downstream of elevated Rac1 in the tumors expres-
sing exogenous p190B. We hypothesize that p190B may
promote tumor formation and progression in part by
affecting Rac/ROS mediated signaling, however, addi-
tional studies will be required to prove this hypothesis.
Rho GTPases including RhoA, Rac1, and Cdc42 are
elevated and hyperactivated in breast cancer [4,5,32].
We, therefore, might have anticipated that exogenous
expression of p190B, an inhibitor of Rho GTPases,
would have tumor suppressor functions. However, our
loss and gain of function studies indicate that p190B has
pro-tumorigenic actions and that it may facilitate tumor
formation and progression in part by modulating Rac1
activity. These results suggest that regulation of Rho
GTPase activity in vivo is likely more complex than
what occurs in cultured cells.
Several lines of evidence suggest that the closely
related p190A RhoGAP functions as a tumor suppres-
sor. For example, p190A is located on chromosome
19q13.3, which is deleted in human gliomas [52]. P190A
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[53] and suppresses platelet derived growth factor
(PDGF) induced glioma formation in mice [54]. Thus,
these two related RhoGAPs may have distinct actions
during tumorigenesis.
Conclusions
P190B RhoGAP, a major inhibitor of the Rho GTPases
in vitro, has pro-tumorigenic functions during mammary
tumor formation and progression. P190B may mediate
its effects on mammary tumorigenesis in part by affect-
ing Rac1 activity. Rho GTPases are overexpressed and
hyperactivated in human breast cancers, and a number
of in vitro and limited in vivo studies indicate that they
function as oncogenes during tumor progression. Thus,
it was intriguing that an inhibitor of the Rho GTPases
has pro-tumorigenic functions during mammary tumor
formation and progression. These studies demonstrate
the importance of investigating the functions of this
complex signaling network in vivo during the stochastic
process of tumor formation and progression.
Additional material
Additional file 1: Supplemental figure 1. Rac and ERK inhibition
disrupt polarity and lumen formation and increase invasion of
primary p190B transgenic and control MEC acini in 3 D culture.
(a) Representative images of phenotypes detected in DMSO control, Rac,
and ERK inhibitor treated 3 D cultures of primary rtTA control and p190B
MECs. Green =αtubulin, Red = pERM (apical polarity marker), and Blue =
nuclei. Arrows indicate invasion into the surrounding matrix. Size bars
represent 10 μm. (b) Quantification of the average number of
invadipodia in vehicle, Rac inhibitor, and ERK inhibitor treated 3 D
cultures (100 structures per experiment were quantified and data
represent n =3 experiments) is graphed. Exogenous p190B expression
resulted in a statistically significant increase in invasion in DMSO vehicle
treated cultures (P = 0.034). Inhibition of Rac and ERK resulted in
statistically significant increases in invasion in control rtTA (P = 0.006 and
P = 0.007, respectively) and in p190B (P = 0.047 and P = 0.039,
respectively) mammary acini. Statistically significant differences were not
detected between genotypes in Rac or ERK inhibitor treated cultures.
T tests were used to compare means and error bars represent standard
error of the mean. (c) Quantification of the percentage of structures with
disrupted lumen formation in DMSO vehicle, Rac inhibitor, and ERK
inhibitor treated 3 D cultures (100 structures per experiment were
quantified and data represent n =3 experiments) is graphed. Exogenous
p190B did not have a statistically significant affect on lumen formation in
DMSO vehicle treated cultures (P > 0.05). Inhibition of Rac and ERK
resulted in statistically significant differences in disruption of lumen
formation in control rtTA mammary acini (P = 0.017 and P = 0.001,
respectively). Disruption of lumen formation was statistically significantly
altered in p190B transgenic mammary acini treated with the ERK
inhibitor (P = 0.001), but not when treated with the Rac inhibitor (P >
0.05). Statistically significant differences were not detected between
genotypes in Rac or ERK inhibitor treated cultures. T tests were used to
compare means and error bars represent standard error of the mean.
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